What type of study is this?

November 30, 2025Brain CommunicationsOpen Access

Five-year disease-modifying therapeutic experience of 102 Chinese pediatric 5q-spinal muscular atrophy: a retrospective analysis

View Full Paper

Ask AI

Bookmark

Retrospective analysis reports improved motor function and 97.08% survival in pediatric 5q-SMA patients with significant complications.

Motor function significantly improved for 5q-SMA patients treated with nusinersen, indicating effective disease-modifying therapy.
Survival rate reached 97.08% during 5 years of follow-up, highlighting treatment efficacy among pediatric cases.
Retrospective analysis of patients at a single center over five years documents treatment outcomes and complications.
Findings support early initiation of treatment protocols to reduce complications such as scoliosis and malnutrition.

A 2025 study studied this question.

View Full Paper

Ask AI

Bookmark

November 30, 2025Brain CommunicationsOpen Access

View Full Paper

Ask AI

Bookmark

Retrospective analysis reports improved motor function and 97.08% survival in pediatric 5q-SMA patients with significant complications.

Motor function significantly improved for 5q-SMA patients treated with nusinersen, indicating effective disease-modifying therapy.
Survival rate reached 97.08% during 5 years of follow-up, highlighting treatment efficacy among pediatric cases.
Retrospective analysis of patients at a single center over five years documents treatment outcomes and complications.
Findings support early initiation of treatment protocols to reduce complications such as scoliosis and malnutrition.

A 2025 study studied this question.

View Full Paper

Ask AI

Bookmark